My PCOS tirzepatide plateau: why not go compounded?

For a few months, the medicine did what you hoped it would. Then the scale stopped moving. You told your telehealth prescriber. The reply was a higher dose. When the weight stalled again, the next reply raised it again. Nobody asked about your PCOS. Nobody drew fasting insulin or checked your thyroid. Nobody told you why a medicine that had been working might stop.

Now the dose is high and the bill has followed it. An email or an ad offers tirzepatide from a compounding pharmacy for less. This piece answers the question that usually follows a PCOS tirzepatide plateau. If the compounded version is cheaper, why not switch? The woman described here is a composite of situations like yours and never a real patient. The eligibility check sits just below if you would rather start there.

The short answer has two parts. GoodLife Health finds the reason for a plateau before it raises the dose. To do that, it reads fasting insulin and thyroid together every quarter. It prescribes branded, FDA-approved GLP-1 only, which means Wegovy, Zepbound, Mounjaro and Ozempic. A cheaper compounded dose answers a question about price. Your question is why the medicine stopped working. A lower price does not answer that one.

Each stall ended with a higher dose

You may have come to tirzepatide after years of advice that explained very little. One clinician suggested fewer carbs. Another offered the pill. Neither drew fasting insulin. When a GLP-1 finally moved the scale, it felt like the first treatment that had taken your body seriously.

The early months went well. Then the weight held at one number for weeks. You sent a message through the app and got back a short note with a new dose. The next stall went the same way. Each time, the answer came quickly and said the same thing. More medicine was the plan. Nobody described another one.

Once you see what was missing, it is easy to list. No one asked what had changed since the medicine started working. No one drew labs that might show something new. No one asked whether a dose that was already high was the right dose for you. No one asked how your PCOS should shape the plan.

The bill moved too. Many telehealth platforms charge more as the dose climbs. Some charge more again when a patient moves from one molecule to another. That pricing is rarely on the homepage. It is on the pricing page, if you know where to look. So when a message arrives offering the same molecule from a compounding pharmacy at a lower price, it reads like relief.

The question that follows is a fair one. If it is the same molecule for less, why pay more? You have spent years paying for care that did not explain itself, so price is a reasonable place to push. The question deserves a straight answer. That answer starts with a different question, which is why the medicine stopped working in the first place.

Why a higher dose was the only answer you heard

Start with what the trials actually show. The SURMOUNT-1 trial followed 2,539 adults. Those on tirzepatide 15 mg lost an average of 20.9% of their body weight over 72 weeks. That is a strong result. It is also an average. Some people lose more and some lose less. The trial excluded many common conditions, so its average is a population result. It cannot tell you what your own body will do. It certainly cannot tell you why yours stopped.

A stall is information worth reading. The first place to read it is the blood. Fasting insulin can be measured before glucose turns abnormal. A1C sits beside it. The thyroid is checked through TSH With Reflex To Free T4. A clinician who reads those numbers beside your dose history has something to reason from. A prescriber who sees only the dose has one lever to pull. When the dose is all the information in front of anyone, a higher dose is the only reply the system can give.

Why would a prescriber see only the dose? Usually the answer lies in the business model. Our white paper, How GLP-1 Telehealth Companies Make Money, describes three ways a telehealth company gets paid when it prescribes a GLP-1. In the most common one, the membership fee looks small and the company earns its margin on the medicine. Its revenue grows with your prescription. The way a company is paid does not make its clinicians good or bad. It decides what the company is rewarded for. In that model, the company earns more from the next dose. A plateau that ends in an escalation email is the business working as designed.

That is the honest reply to the line you have seen in so many ads: “I can get the prescription for $99 online.” A low fee is possible because the money is made somewhere else. You are entitled to know where.

Now the compounded question itself. A compounded GLP-1 is mixed by a pharmacy from raw ingredients. It is not made by the manufacturer and is not reviewed by the FDA for safety or effectiveness. Federal law allowed pharmacies to copy tirzepatide while it sat on the FDA's drug shortage list. The FDA declared that shortage resolved in December 2024. The last enforcement grace period for tirzepatide compounding ended on March 19, 2025. In 2026, the FDA proposed permanently excluding tirzepatide and semaglutide from the list outsourcing facilities may compound in bulk. Both manufacturers have sued companies selling compounded versions. What remains is a narrow exception for one patient with a documented clinical need the branded product cannot meet, such as an allergy to an ingredient. The FDA sets out its concerns about unapproved GLP-1 drugs on its own site.

None of this is a judgment of any one pharmacy or any one patient. Millions of people used compounded copies legally during the shortage and did nothing wrong. The record matters for a different reason. A clinician carries the responsibility for a prescription on their licence. GoodLife Health's clinicians prescribe only what the FDA has approved. That choice means our members pay the branded price, which is higher. We made it anyway.

Then there is the plateau. Moving to a compounded version moves your dose to a cheaper supplier. It keeps the plan that stalled. A cheaper dose makes the next escalation easier to afford. It leaves the plateau exactly as unexplained as it was. If it stopped working, someone should find out why before the dose goes up.

What GoodLife Health does with a stalled dose

GoodLife Health is precision direct primary care for Cardiometabolic Optimization. For a stalled GLP-1, that comes down to one thing in practice. It finds the reason before it raises the dose.

The path has four steps. You start with the eligibility check, then an intake about your history, your medication and your dose. At checkout, $598 is held on your card to cover the first two months. A clinician then reviews your application. Not everyone is accepted. If the clinician cannot accept you into care, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month at $299.

Once you are a member, the panel comes first. It is drawn four times a year and includes fasting insulin, A1C and TSH With Reflex To Free T4 among its cardiometabolic markers. Every result is in your hands. Your clinician reads those numbers beside your dose history and the date the weight stopped moving. Whether the dose then goes up, holds or comes down is a decision your clinician makes with you. If you are coming from a compounded GLP-1, the clinician reviews your current dose and decides with you how to proceed.

The clinician stays. Between visits, you message the care team. When a conversation needs a face, there are video visits. The next quarter's panel shows whether the plan is doing what it was meant to do, so your markers are followed over time.

Medication is unbundled from the membership. When a branded GLP-1 is clinically indicated, it is prescribed to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing on it, sees nothing of it and takes nothing from it. For a sense of scale, Lilly's published self-pay price for Zepbound vials through LillyDirect was $299 to $449 a month in September 2026, depending on dose. That is more than a compounded copy usually costs. You pay it to the pharmacy. GoodLife Health takes none of it. Whether insurance covers a medication is between you, your plan and your pharmacy. We never promise coverage. Prior authorization is the pharmacy's process and GoodLife Health does not run it or speed it up.

The membership fee is the same whatever medication is indicated and whatever the dose. There is no molecule upcharge and no dose upcharge. We call this Medication-Neutral Pricing and it is the structural answer to the escalation emails. When the fee cannot rise with the dose, nothing in the business rewards a higher one. Our guide to Aligned Medicine explains how that structure works and how to check it for yourself.

What the membership does not do matters as much. It does not prescribe compounded GLP-1. It does not promise a number on the scale or any typical result. It does not replace your insurance, which you keep for catastrophic cover. It replaces the primary-care relationship for your cardiometabolic care.

What to do before the next dose, whether or not you join

We do not know why your weight stopped moving. Nobody does until the labs are read. That is the point of this piece. Here are five things you can do this week with any prescriber.

1. Write down your dose history and the date the scale stopped moving. A clinician can do more with dates than with a feeling.
2. Before the next increase, ask your current prescriber to order fasting insulin, A1C and TSH With Reflex To Free T4. If the answer is no, ask why.
3. Read your platform's pricing page and check whether your monthly bill changes with your dose.
4. If you are offered compounded tirzepatide, ask which pharmacy makes it and on what basis it is compounded now that the shortage has ended.
5. Look up the manufacturer's self-pay price yourself, so you know what branded medication costs at its source.

Medicine is moving toward testing before treating. Fasting insulin is now read where glucose alone used to be read. Manufacturers now publish their own self-pay prices with dates. You can ask for both of those things anywhere. A plateau is a good reason to start.

Who this is not for

If the lowest monthly price for a dose shipped to your door is what you want, a low-fee app built on medication margin will give you that. We would rather say so plainly than sign you up. If you want compounded tirzepatide, we will not prescribe it. If you want a promise about the scale, we cannot make one. Anyone who does is guessing. If you do not want blood drawn four times a year, this model is built around exactly that. If you live outside the United States, we cannot care for you. If you hoped a membership would replace health insurance, this one will not. Keep your insurance for the hospital.

For everyone else, the offer is this. The membership is $299 a month. At sign-up, $598 is held on your card for the first two months and is charged only once a clinician accepts you. If you are not accepted, the hold is released and you are never charged. Once you are accepted, those two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own refund policy. After that, the membership runs month to month, which comes to $3,588 a year. It buys four cardiometabolic panels a year, a clinician who stays and medication sent to your pharmacy at that pharmacy's price with nothing taken on it. It returns the diagnosis that escalation emails and eight-minute visits never produced, with your markers followed over time. We test first and treat second. We sell neither the drug nor the dose. If your next increase is already scheduled, the time to test is before it.

Related Reading

• How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
• Aligned Medicine: How Zero-Markup Healthcare Actually Works

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
3. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings